Sage Therapeutics' rare disease drug meets main goal in mid-stage study

Sage Therapeutics

11/06/2024 11:38

June 11 (Reuters) - Sage Therapeutics  SAGE.O  said on
Tuesday its experimental drug met the main goal of a mid-stage
study in patients with a type of rare disease known as
Huntington's disease.

 (Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh
Kuber)
 ((Sriparna.Roy@thomsonreuters.com;))